EUVIMEDEUVIMED entdecken
Crossref

The utility of interleukin-23 intraclass switching in the treatment of plaque psoriasis: a retrospective review of 43 cases

M Grace Hren, Sreekar Miriyala, Saakshi Khattri

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llae305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von M Grace Hren und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Interleukin-23. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin (IL)-23 inhibitors are a class of injectable biologics, which include risankizumab, tildrakizumab and guselkumab, used for the treatment of moderate-to-severe psoriasis. This retrospective review sought to determine the value of IL-23 inhibitor intraclass switching among patients with psoriasis after they experienced loss of efficacy to any IL-23 inhibitor. We conducted a retrospective chart review, including 43 patients who underwent any of 6 potential iterations of IL-23 intraclass switching between November 2017 and November 2023. Most commonly, patients switched from guselkumab or tildrakizumab to risankizumab (84%). On average, patients failed 2.3 biologic treatments (SD 1.3) prior to switching. Postswitching, 81% of patients achieved an affected body surface area (BSA) < 1% after 248.8 days (SD 126.5). BSA immediately prior to intraclass switch was 13.1 (SD 8.9) [95% confidence interval (CI) 10.4–15.8] and at most recent follow-up was 2.9 (SD 5.2) (95% CI 2.3–5.5). This research adds to a growing body of literature demonstrating the potential of IL-23 intraclass switching in the treatment of moderate-to-severe plaque psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedInterleukin-23HumansRetrospective StudiesFemaleMaleMiddle AgedAdultAntibodies, MonoclonalDrug SubstitutionSeverity of Illness IndexDermatologic AgentsTreatment OutcomeAged

Substanzen

Antibodies, Monoclonal, HumanizedguselkumabtildrakizumabrisankizumabInterleukin-23Antibodies, MonoclonalDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Zitieren

APA

Hren, M. G., Miriyala, S., & Khattri, S. (2024). The utility of interleukin-23 intraclass switching in the treatment of plaque psoriasis: a retrospective review of 43 cases. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae305

Vancouver

Hren MG, Miriyala S, Khattri S. The utility of interleukin-23 intraclass switching in the treatment of plaque psoriasis: a retrospective review of 43 cases. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae305

BibTeX
@article{Hren2024,
  author = {Hren, M Grace and Miriyala, Sreekar and Khattri, Saakshi},
  title = {The utility of interleukin-23 intraclass switching in the treatment of plaque psoriasis: a retrospective review of 43 cases},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llae305}
}
Kostenlos starten →